Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: ATL administration
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Lukas Biomedical Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05304481
- Locations
- 🇨🇳
Hualien Tzu Chi Hospital, Hualien City, Taiwan
🇨🇳E-Da Cancer Treatment Hospital, Kaohsiung, Taiwan
🇨🇳Far Estern Memorial Hospital, New Taipei City, Taiwan
© Copyright 2025. All Rights Reserved by MedPath